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Abstract
Background: MiR-106b-25 cluster, hosted in intron 13 of MCM7, may play integral roles in diverse processes including
immune response and tumorigenesis. A single nucleotide polymorphism (SNP), rs999885, is located in the promoter region
of MCM7.
Methods: We performed a case-control study including 1300 HBV-positive hepatocellular carcinoma (HCC) cases, 1344 HBV
persistent carriers and 1344 subjects with HBV natural clearance to test the association between rs999885 and the risk of
HBV persistent infection and HCC. We also investigated the genotype-expression correlation between rs999885 and miR-
106b-25 cluster in 25 pairs of HCC and adjacent non-tumor liver tissues.
Results: Compared with the HBV natural clearance subjects carrying rs999885 AA genotype, those with AG/GG genotypes
had a decreased risk of chronic HBV infection with an adjusted odds ratio (OR) of 0.79 [95% confidence intervals (CIs)=0.67–
0.93]. However, the AG/GG genotypes were significantly associated with an increased HCC risk in HBV persistent carriers
(adjusted OR=1.25, 95% CIs=1.06–1.47). Expression analysis revealed that the expression level of miR-106b-25 cluster was
significantly higher in AG/GG carriers than those in AA carriers in non-tumor liver tissues.
Conclusions: These findings indicate that the A to G base change of rs999885 may provide a protective effect against
chronic HBV infection but an increased risk for HCC in HBV persistent carriers by altering the expression of the miR-106b-25
cluster.
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Introduction
Hepatocellular carcinoma (HCC) is one of the major cancer
burdens in China [1]. Hepatitis B virus (HBV) infection has been
well established as a risk factor for liver carcinogenesis [2]. HBV
persistent infection or HBV natural clearance is influenced by
complex factors of viral, host age, environmental and genetic
makeup, while hereditary factors may also play critical roles in
the pathogenesis of HCC, together with other environmental
factors, such as cigarette smoking, alcohol drinking and aflatoxins
ingestion [3,4].
MicroRNAs (miRNAs) are small non-coding RNAs that may
regulate genes expression, either by inhibiting target mRNA
translation or inducing its degradation [5]. Alterations of miRNA,
including expression disorders and mutations, are involved in the
initiation and progression of human cancers [6]. Accumulating
data revealed that a subset of miRNAs deregulated in HCC
[7,8,9,10,11]. Among them, miR-106b-25 cluster, including miR-
106b, miR-93 and miR-25, is of particular interest, for its integral
roles in diverse processes including immune response and
tumorigenesis [11,12,13]. The cluster is hosted in intron 13 of
MCM7, the abbreviation of minichromosome maintenance
complex component 7, and Petrocca et al indicated that its
transcription might be driven by the host gene [14]. We searched
single nucleotide polymorphisms (SNPs) in the promoter region of
MCM7 with the criteria of minor allele frequency (MAF).0.05 in
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high linkage disequilibrium (LD) (r-square=1). We chose
rs999885 and performed a case-control study including 1300
HBV positive HCC cases, 1344 HBV persistent carriers and 1344
HBV natural clearance subjects to test the association between this
SNP and risk of HBV persistent infection and HCC.
Methods
Study Subjects
This case-control study was approved by the institutional review
board of Nanjing Medical University. The subjects’ enrollment
was described previously [15]. In brief, the newly diagnosed HCC
patients were consecutively recruited from January 2006 to
December 2010 at the Nantong Tumor Hospital, the Qidong
liver cancer institute of Jiangsu Province and the First Affiliated
Hospital of Nanjing Medical University, Jiangsu, China. The
controls were screened for the HBV/HCV markers from two cities
in Jiangsu Province (9720 persons from Changzhou and 48422
persons from Zhangjiagang) in 2004 and 2009, respectively.
About 865 (8.9%) HBV persistent carriers and 1759 (18.1%)
subjects with HBV natural clearance were identified from
Changzhou; while 2156 (4.5%) HBV persistent carriers and
7851 (16.2%) subjects with HBV natural clearance were identified
from Zhangjiagang. We randomly selected 1344 HBV persistent
carriers and 1344 HBV natural clearance people from the two
cities and matched to the HCC cases on age and gender. HBV
persistent carriers were positive for both HBV surface antigen
(HBsAg) and antibody to hepatitis B core antigen (anti-HBc),
negative for HCV antibody (anti-HCV). Subjects with HBV
natural clearance were negative for HBsAg and anti-HCV, plus
positive for both antibody to hepatitis B surface antigen (anti-HBs)
and anti-HBc.
Serological testing
HBsAg, anti-HBs, anti-HBc and anti-HCV were detected by
the enzyme-linked immunosorbent assay (Kehua Bio-engineering
Co., Ltd., Shanghai, China) in the serum following the
manufacturer’s instructions as described previously [15].
SNPs Genotyping
Genomic DNA was extracted from a leukocyte pellet by
traditional proteinase K digestion, phenol-chloroform extrac-
tion and ethanol precipitation. The SNP, rs999885 A.G
was genotyped by using the TaqMan allelic discrimination
assay on a 7900 system (Applied Biosystems). The primers
and probes for rs999885 were designed as follows: Primers:
sense, F59-CATCCAAAGCAATCAATCATCAG, antisense,
59-GGCTTGGTCAGTAGAGGGAAAG; Probes: allele G,
FAM-CCCTCTTCTCTTTC-MGB, allele A, HEX-
CCCTCTTTTCTTTC-MGB. The genotyping was performed
without knowing the subjects’ case or control status. Two blank
(water) controls in each 384-well plate were used for quality
control and more than 5% samples were randomly selected and
repeated, yielding a 100% concordant.
Tissue Samples
We collected 25 pairs of HCC and adjacent non-tumor
liver tissues from the patients who had undergone surgery
between April 2008 and October 2010 from the Nantong Tumor
Hospital. All cases were histopathologically diagnosed as HCC
and had no radiotherapy or chemotherapy before surgical
operation.
Quantitative Reverse Transcriptase–Polymerase Chain
Reaction (RT-PCR)
Quantitative RT-PCR was performed to determine the
expression level of miR-106b-25 cluster with Power SYBR Green
PCR Master Mix (Applied Biosystems Inc.) and the primers were
shown in Fig. 1A. Normalization was performed with b-actin
(sense, 59- AGAAAATCTGGCACCACACC -39, antisense, 59-
GGGGTGTTGAAGGTCTCAAA -39). All PCR reactions,
including no-template controls and real-time minus controls, were
performed in triplicate. A relative expression was calculated using
the equation 2
2DCt, in which DCt=Ctgene2Ctb-actin, and also the
equation 2
2DDCt, in which DDCt=(Ctnormal2Ctb-actin-normal)2
(Cttumor2Ctb-actin-tumor).
Statistical Analysis
The Student’s t-test and x
2 test were used to detect differences
of demographic characteristics, genotype frequencies of the SNP
between the cases and controls for continuous variables and
categorical variables, respectively. Associations between the
genotypes and risk of HCC or HBV persistent infection were
estimated by computing odds ratios (ORs) and their 95%
confidence intervals (CIs) from logistic regression analyses. The
crude ORs were calculated from univariate logistic regression,
while the adjusted ORs were from multivariate logistic regression
with the adjustment for age, gender, drinking and smoking status.
The Chi-square-based Q test was applied to test the heterogeneity
of associations between subgroups. Expression levels of miR-106b-
25 between different groups were compared by the Mann-
Whitney U test. All of the statistical analyses were performed with
R software (version 2.13.0; The R Foundation for Statistical
Computing). All tests were two-sided.
Results
The demographic characteristics of the 1300 HBV positive
HCC cases, 1344 HBV persistent carriers and 1344 persons with
HBV natural clearance have been summarized previously [15].
Briefly, no significant differences were detected in the age and
gender distributions between the three groups (P=0.839 and
0.716, respectively). Smoking rates were also similar between the
three groups. However, the drinking rates were higher among
cases than that in controls (P,0.001 for both HCC cases compare
to HBV persistent carriers and clearance controls).
The genotyping call rate for rs999885 was 98.65%. The
genotype distributions of rs999885 in HBV positive HCC cases,
HBV persistent carriers and HBV natural clearance subjects are
shown in Table 1. In the logistic regression analyses between HBV
persistent carriers and HBV natural clearance subjects, it was
shown that the variant genotypes (AG/GG) of rs999885 were
associated with a significantly decreased risk for chronic HBV
infection (adjusted OR=0.79, 95% CIs=0.67–0.93, P=0.004) in
the dominant genetic model. However, compared with the HBV
persistent carriers carrying wild-type AA of rs999885, those with
the AG genotype had an increased risk for HCC with adjusted OR
of 1.28 (95% CIs=1.08–1.52), and the AG/GG genotypes had an
increased risk by 25% (adjusted OR=1.25, 95% CIs=1.06–1.47,
P=0.008) (Table 1).
The association between rs999885 and the susceptibility to
HCC and HBV persistent infection was also evaluated by
stratifying on age, gender, drinking and smoking status (Table
S1). However, no significant heterogeneity was detected between
the subgroups, implying independent genetic effect of rs999885.
To characterize the functional relevance of the SNP rs999885,
we conducted a correlation analysis between the rs999885
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PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e32230Figure 1. Genotype–expression correlations for rs999885 and miR-106b-25 cluster expression levels. (A) The positions and sequences
of the primers used for RT-PCR to quantify the level of miR-106b-25 cluster are indicated. (B, C) Quantitative RT-PCR was used to measure expression
levels of miR-106b-25 cluster in 25 pairs of HCC and adjacent non-tumor liver tissues. Normalization was performed by the b-actin. Genotype–
expression correlations for genotypes and expression levels of miR-106b-25 cluster in normal and tumor tissues, respectively, which were calculated
by using the equation 2
2DCt, and DCt=Ctnormal(Cttumor)2Ctb-actin-normal(Ctb-actin-tumor). (D) Genotype–expression correlation for rs999885 and
the expression level of miR-106b-25 cluster, which was calculated by using the equation 2
2DDCt, and DDCt=(Ctnormal2Ctb-actin-normal)2(Cttumor2
Ctb-actin-tumor).
doi:10.1371/journal.pone.0032230.g001
Table 1. Genotype frequencies of rs999885 and susceptibility of HCC and HBV persistent infection.
Genotype
HCC
patients
HBV persistent
carriers
HBV natural clearance
subjects OR(95%CI)
a P OR(95%CI)
b P
(N=1300) (N=1344) (N=1344)
rs999885 n % n % n %
AA 815(63.1) 902(68.0) 823(62.6) 1 1
AG 439(34.0) 381(28.7) 454(34.5) 1.28(1.08–1.52) 0.77(0.65–0.90)
GG 38(2.9) 44(3.3) 38(2.9) 0.96(0.61–1.51) 1.06(0.68–1.66)
AG/GG 477(36.9) 425(32.0) 492(37.4) 1.25(1.06–1.47) 0.008 0.79(0.67–0.93) 0.004
NOTE: Multivariate logistic regression analyses adjusted for age, sex, smoking status and drinking status.
aHCC patients vs. HBV persistent carriers.
bHBV persistent carriers vs. HBV natural clearance subjects.
doi:10.1371/journal.pone.0032230.t001
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found that, in the 25 pairs of tissue specimens, 8 had the rs999885
AA genotype, 16 with the AG genotype, and 1 with the GG
genotype. As shown in Fig. 1B, the expression levels of miR-106b-
25 were significantly higher in AG/GG carriers than those in AA
carriers in normal liver tissues (0.02460.033 for AG/GG vs.
0.00660.017 for AA, P=0.016). Furthermore, as shown in
Fig. 1D, the relative expression levels between HCC and normal
liver tissues of miR-106b-25 were also higher in AG/GG carriers
than those in AA carriers (20.633630.152 for AG/GG vs.
3.394612.090 for AA, P=0.043).
Discussion
In this study, we investigated the association between rs999885
and the susceptibility to HBV persistent infection and HCC in a
Chinese population. We found that the A to G base change of
rs999885 demonstrated protective effect on chronic HBV
infection, but increased the risk of HCC in HBV persistent
carriers.
To date, accumulating data has showed that miR-106b-25
cluster plays oncogenic roles in cancers, through influencing tumor
growth, cell survival, and angiogenesis [16,17,18]. This cluster has
been reported to be up-regulated in several cancers, including
esophageal adenocarcinoma [18], gastric cancer [19], prostate
cancer [20], head and neck squamous cell carcinoma [21], and
HCC [11]. Specially, by sequencing analysis, it was shown that the
expression levels of miR-106b, miR-93 and miR-25 were higher in
liver cancer cell lines than those in normal liver cells [22]. In this
study, we found that the expression levels of miR-106b-25 were
significantly higher in AG/GG carriers, which was consistent with
the risk effect of the variant genotypes. However, reverse findings
were reported in immune disorders. De Santis et al found that
miR-106b-25 down-regulated in multiple sclerosis patients com-
pared to healthy donors in specific T regulatory cells [23], which
might support the protective role of the variant genotypes of
rs999885 on susceptibility to chronic HBV infection. In addition,
several independent studies also revealed that miR-106b-25 cluster
promoted cell cycle progression by suppressing the Cip/Kip family
members of Cdk inhibitors, in which miR-25 targeted p57, while
miR-106b and miR-93 controlled p21 [17,24,25]. Moreover, the
miR-106b-25 cluster may resist the TGF-b tumor suppression
pathway [26], and miR-93 alone may promote tumor growth and
angiogenesis by suppressing integrin-b8 expression [16].
The miR-106b-25 polycistron is activated by genomic ampli-
fication and over-expression of MCM7 [27], and the miR-106b-25
cluster may cooperate with its host gene MCM7 in cellular
transformation [28]. The SNP rs999885 (A.G) is located at
1749-bp upstream from transcriptional start position of MCM7.
According to the web-based SNP analysis tool (TFSEARCH 1.3),
the A allele of rs999885 may have high affinity with a transcription
factor, sex-determining region Y protein (SRY), which involved in
gene regulation including promoter activation or repression
depending on its interacted protein [29,30]. In the current study,
we provided evidence that the rs999885 variant could influence
miR-106b-25 expression.
In summary, this study, with a relative large population, showed
that a genetic variant in the promoter region of miR-106b-25
cluster might provide a protective effect against chronic HBV
infection but an increased risk for HCC in HBV persistent carriers
by affecting the expression of miR-106b-25 cluster. Further studies
incorporating diverse populations and functional assays are
warranted to validate and extend our findings.
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